Intravascular Imaging-Guided Versus Angiography-Guided PCI:

1

Systematic Review and Meta-analysis of 24 Randomized Controlled Trials 2 3 David Hong, MD^{1*}, Woochan Kwon, MD^{1*}, Seung Hun Lee, MD, PhD^{2†}, Doosup Shin, MD³, 4 5 Hyun Kuk Kim, MD, PhD⁴, Kwan Yong Lee, MD, PhD⁵, Eun Ho Choo, MD, PhD⁵, Sung Eun Kim, MD⁶, Young Joon Hong, MD, PhD², Young Keun Ahn, MD, PhD², Myung Ho Jeong, 6 MD, PhD², Junho Ha, MD¹, Minseok Hong, MD¹, Ki Hong Choi, MD, PhD¹, Taek Kyu Park, 7 MD, PhD¹, Jeong Hoon Yang, MD, PhD¹, Young Bin Song, MD, PhD¹, Joo-Yong Hahn, MD, 8 PhD¹, Seung-Hyuk Choi, MD, PhD¹, Hyeon-Cheol Gwon, MD, PhD¹, Joo Myung Lee, MD, 9 MPH, PhD^{1†}, The RENOVATE COMPLEX-PCI Investigators 10 11 * DH and WK contributed equally as the first authors. 12 [†] SHL and JML contributed equally as the corresponding authors. 13 14 ¹Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; 15 ²Department of Internal Medicine and Cardiovascular Center, Chonnam National University 16 Hospital, Gwangju, Korea; ³Division of Cardiology, Department of Internal Medicine, Duke 17 University Medical Center, Durham, NC, USA; ⁴Department of Internal Medicine and 18 Cardiovascular Center, Chosun University Hospital, University of Chosun College of Medicine, 19 Gwangju, Korea; ⁵Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea; 20 ⁶Department of Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. 21 22 Running title: A Meta-analysis of Intravascular Imaging-Guided PCI 23

1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

2 Word count:

- 3 Manuscript 3,584 (not including abstract, tables, figures, acknowledgments, references, and
- 4 online-only material)
- 5 Number of Tables and Figures -1/5
- 6

7 Address for correspondence:

- 8 Seung Hun Lee, MD, PhD
- 9 Division of Cardiology, Department of Internal Medicine, Chonnam National University
- 10 Hospital, Chonnam National University Medical School, 42, Jebong-ro, Dong-gu, Gwangju
- 11 61469, Republic of Korea
- 12 Tel; 82-10-6413-7449, Fax; 82-2-6455-1449
- 13 E-mail; lsh8602@naver.com, gfmaniac@gmail.com
- 14
- 15 Joo Myung Lee, MD, MPH, PhD
- 16 Department of Internal Medicine and Cardiovascular Center,
- 17 Heart Vascular Stroke Institute, Samsung Medical Center,
- 18 50, Irwon-dong, Gangnam-gu, Seoul 135–710, Republic of Korea
- 19 Telephone: 82-2-3410-3391; Fax: 82-2-3410-6278
- 20 E-mail: drone80@hanmail.net, joomyung.lee@samsung.com

1 Abstract

Objective: To evaluate comparative prognosis between intravascular imaging-guided PCI and
 angiography-guided PCI using a comprehensive meta-analysis including all previous
 randomized controlled trials.

5 **Design**: Systematic review and meta-analysis of randomized controlled trials.

6 Data Sources: Target trials were selected by a systematic electronic search strategy in the

7 PubMed, EMBASE, and Cochrane databases from their inception to Sep, 2023.

8 Study Selection: Published randomized controlled trials which compared clinical outcomes

9 between intravascular imaging-guided and angiography-guided PCI were included.

Main Outcome and Measures: Major adverse cardiac events (MACE), all-cause death,
myocardial infarction (MI), target vessel revascularization (TVR), and stent thrombosis.

12 **Review Methods:** Random-effects model was used to calculate pooled relative risk (RR) and

13 95% confidence interval (CI) between intravascular imaging-guided and angiography-guided

14 PCI. Heterogeneity was assessed by I^2 values.

15 **Results:** Among a total of 14,037 patients (7,383 in intravascular imaging-guided PCI and

16 6,654 in angiography-guided PCI groups), intravascular imaging-guided PCI was associated

17 with a lower risk of MACE than angiography-guided PCI (RR, 0.75; 95% CI, 0.67 to 0.84;

18 P<0.001; I², 18.9%), driven by lower risk of MI (RR, 0.83; 95% CI, 0.70 to 0.97; P=0.019; I²,

19 0.0%), TVR (RR, 0.70; 95% CI, 0.61 to 0.79; P<0.001; I², 0.0%), and stent thrombosis (RR,

20 0.50; 95% CI, 0.32 to 0.78; P=0.002; I^2 , 0.0%). There was no difference in the risk of all-cause

21 death (RR, 0.82; 95% CI, 0.67 to 1.01; P=0.068; I^2 , 0.0%), however, trials with 2^{nd} generation

- 22 drug-eluting stent (DES) showed significant reduction of all-cause death following
- 23 intravascular imaging-guided PCI (RR, 0.77; 95% CI, 0.61 to 0.95; P=0.018; I², 0.0%).

1	Conclusions: Compared to angiography-guided PCI, intravascular imaging-guided PCI was
2	associated with a reduced the risk of MACE, by lowering the risks of MI, TVR, and stent
3	thrombosis. Pooled analysis of trials with 2 nd generation DES showed significantly lower risk
4	of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI.
5	
6	Systematic Review Registration: PROSPERO, CRD42023402677
7	
8	Key Words: Coronary artery disease; Percutaneous coronary intervention; Intravascular

- 9 ultrasound; Optical coherence tomography; Meta-analysis.

1 Summary Boxes

2 What is already known on this topic

- Due to limited sample size, previous randomized controlled trials (RCTs) were not
 able to show significant differences in the risks of hard clinical events such as death,
 myocardial infarction (MI), or stent thrombosis between intravascular imaging guided percutaneous coronary intervention (PCI) and angiography-guided PCI.
- Although previous meta-analyses showed that intravascular imaging-guided PCI
 resulted in a lower risk of death or MI than angiography-guided PCI, inclusion of both
 observational studies and RCTs caused heterogeneity and lowered the evidence level
 of the results.

11 What this study adds

- The current meta-analysis exclusively included 24 RCTs and showed that
 intravascular imaging-guided PCI significantly reduced the risk of major adverse
 cardiac events (MACE), compared with angiography-guided PCI.
- It should be noted that intravascular imaging-guided PCI reduced not only the risk of
 target-vessel revascularization but also the risks of hard clinical events such as MI
 and stent thrombosis.

1 Abbreviations

- 2 CI = confidence interval
- 3 DES = drug-eluting stent
- 4 IVUS = intravascular ultrasound
- 5 MACE = major adverse cardiac events
- 6 MI = myocardial infarction
- 7 OCT = optical coherence tomography
- 8 OR = odds ratio
- 9 PCI = percutaneous coronary intervention
- 10 RCT = randomized controlled trial
- 11 TVR = target vessel revascularization

12

Introduction

1

2 Percutaneous coronary intervention (PCI) is one of the important treatment options for 3 patients with coronary artery stenosis. Despite improvement of drug-eluting stent (DES) platforms and PCI techniques, it is still unclear whether PCI can reduce death or myocardial 4 infarction (MI) compared with guideline-directed medical treatment alone,^{1 2} and PCI for 5 complex coronary artery lesions is challenging in daily practice due to increased risk of stent 6 failure.³⁻⁵ Therefore, continuous efforts have been made to find how to guide and optimize PCI 7 8 to improve clinical outcomes. In this regard, intravascular imaging using intravascular ultrasound (IVUS) and optical coherence tomography (OCT) would be useful by providing 9 10 information on lesion characteristics, reference vessel size, stent expansion and apposition, and acute complications.⁶ 11

Previous randomized controlled trials (RCTs) have shown lower rates of major adverse 12 cardiac events (MACE) after intravascular imaging-guided PCI than after angiography-guided 13 PCI,⁷⁻²⁸ although it mainly reduced the risk of repeat revascularization without significant 14 difference in hard clinical events such as death, MI, or stent thrombosis. In contrast, the recently 15 16 published RENOVATE-COMPLEX-PCI (Randomized Controlled Trial of Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After Complex 17 Percutaneous Coronary Intervention) firstly demonstrated a superiority of intravascular 18 19 imaging-guided PCI over angiography-guided PCI in patients with complex coronary artery lesions, mainly driven by reduced risk of cardiac death and MI with intravascular imaging 20 guidance. The OCTOBER (European Trial on Optical Coherence Tomography Optimized 21 22 Bifurcation Event Reduction) trial also showed the prognostic benefit of OCT-guided PCI over angiography-guided PCI in patients with complex bifurcation lesions.²⁹ Conversely, ILUMIEN 23 IV (OPtical Coherence Tomography [OCT] Guided Coronary Stent IMplantation Compared to 24

Angiography: a Multicenter Randomized TriaL in PCI) failed to show significant difference in
 target vessel failure between the two strategies in patients with diabetes mellitus or complex
 coronary artery lesions.³⁰

4 Therefore, we conducted an updated meta-analysis using all available RCTs to date to 5 investigate whether intravascular imaging-guided PCI would improve clinical outcomes 6 compared with angiography-guided PCI.

7

8 Methods

9 Data Sources and Searches

10 PubMed, EMBASE, Cochrane Central Register of Controlled Trials, the United States National Institutes of Health registry of clinical trials, and relevant websites were searched for 11 pertinent published or unpublished studies from inception to September 2023. The electronic 12 search strategy was complemented by manual examination of references cited by included 13 articles, recent reviews, editorials, and meta-analyses. No restrictions were imposed on study 14 period or sample size, but only articles in English were considered. Keywords included 15 16 'intravascular ultrasound, 'optical coherence tomography', 'PCI', 'percutaneous coronary intervention', 'coronary stenting', 'stenting', 'stent', 'stent implantation', 'angiography', 'impact', 17 'outcome', 'randomized', and 'randomized clinical trial' (Supplemental Table 1). The present 18 19 study complied with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.³¹ The study protocol was prespecified and registered with PROSPERO 20 (CRD42023402677). Institutional Review Board (IRB) of Samsung Medical Center waived 21 22 IRB approval process based on the study design, which is the study-level meta-analysis using 23 published materials.

24

1 Study Selection

Studies were included if they met the following prespecified criteria: (1) RCTs 2 comparing intravascular imaging-guided PCI versus angiography-guided PCI in patients with 3 coronary artery disease; (2) clinical outcome assessment with follow-up duration of at least 1 4 month; and (3) clinical outcomes including all-cause death, cardiac death, MI, target vessel 5 6 revascularization (TVR), or stent thrombosis. Non-randomized studies, duplicated reports of 7 previous RCTs, or post-hoc analysis including cost-effectiveness analysis of reported RCTs 8 were not included (Supplemental Table 2). Two independent investigators (D.H. and W.K.) screened titles and abstracts, identified duplicates, performed full-article reviews, and 9 determined inclusion. Two other investigators (S.H.L. and J.M.L.) supervised the search and 10 adjudicated disagreements. 11

12

13 Data Extraction and Quality Assessment

Summary data as reported in the published manuscripts were analyzed. A standardized 14 form was used to extract study characteristics; trial design; number of trial population; median 15 16 follow-up duration; type of intravascular imaging devices; demographics; clinical and angiographic eligibility criteria, including clinical diagnosis and angiographic lesion 17 characteristics; proportion of cardiovascular risk factors; and used stent types. The rates of all-18 19 cause mortality, MI, TVR, stent thrombosis, and MACE were collected, along with the 20 definition of clinical events, as reported on an intention-to-treat basis. For trials which used both IVUS and OCT, group size and number of events were separately extracted, according to 21 22 the type of intravascular imaging devices. In trials with available reports for both short- and 23 long-term clinical outcomes, those with the longest follow-up duration were used in the current meta-analysis. In addition, unadjusted results of clinical events were used in the current meta-24

1 analysis.

The quality of eligible trials was assessed using the Cochrane Collaborations tool Version 2 for assessing the risk of bias in RCTs regarding random sequence generation, allocation concealment, blinding of participants and outcome assessment, incomplete outcome assessment, or selective reporting. We did not exclude individual studies from the analysis based on the risk of bias in RCTs.

7

8 Outcomes and Definitions

9 The primary outcome was MACE at the longest available follow-up. Since the 10 definition of MACE or composite outcomes varied across the trials, we used representative 11 composite outcome reported under intention-to-treat principle in the included trials. The 12 definition of MACE used in the included trials are presented in **Supplemental Table 3**. In most 13 trials, MACE was a composite of all-cause death, MI, and TVR. Secondary outcomes included 14 all-cause death, MI, TVR, and stent thrombosis.

15

16 Data Synthesis and Analysis

Primary and secondary outcomes were analyzed using random-effects models. 17 Relative risks (RRs) with 95% confidence intervals (CIs) were presented as summary statistics. 18 19 Because all included studies showed heterogeneity regarding study protocol and populations, 20 fixed-effects models were only used for sensitivity analyses to check whether these models yielded similar results. The pooled RRs and 95% confidence intervals were calculated using 21 22 the DerSimonian and Laird method for random effects, as well as the Mantel-Haenszel method 23 for fixed effects. Because of progressive changes in primary study designs and clinical practice patterns, especially type of used stents (bare metal stent, 1st or 2nd generation DES), we 24

1 evaluated the impact of publication date on the overall effect of pooled RRs for the risk of 2 MACE by a cumulative meta-analysis. Since all of the included trials in the cumulative meta-3 analysis had the same comparison groups, cumulative pooled effect estimates up to time point of last study inclusion could reflect temporal trends in effect size (RR). Statistical heterogeneity 4 was quantified with the I^2 statistics. I^2 values <25%, 25% to 50%, and >50% indicate low, 5 6 moderate, and high degrees of heterogeneity, respectively. Small study bias (publication bias) 7 was assessed by funnel plot asymmetry and Egger's and Begg's tests; when visual asymmetry 8 of funnel plot was suspected, the trim-and-fill method was used to estimate the number of 9 missing studies and to calculate a corrected RR, as if these studies were present. The influence 10 of an individual study was explored by estimating pooled RRs, with stepwise exclusion of one 11 study.

Subgroup analyses were performed to determine whether effects differed across 12 subgroups. These subgroups analyses were analyzed: (1) type of intravascular imaging devices 13 (IVUS or OCT); (2) angiographic characteristics (all-comers population or patients with 14 15 complex coronary artery disease); (3) type of complex coronary artery lesions (chronic total 16 occlusion, left main disease, or diffuse long lesion); (4) type of used stents (bare metal stent, 1st or 2nd generation DES); (5) clinical presentation (stable ischemic heart disease or acute 17 coronary syndrome); and (6) presence of cardiovascular risk factors (diabetes mellitus or 18 19 chronic kidney disease). Random-effects meta regression analysis was performed to evaluate differential effect size of intravascular imaging-guided PCI for MACE according to each 20 subgroup. Two-sided P-values <0.05 were considered statistically significant. Statistical 21 22 analysis was performed using STATA/SE 12.0 (Stata Corp LP, College Station, Texas, USA) and R programming language, version 4.2.2 (R Foundation for Statistical Computing, Vienna, 23 Austria). 24

11

1

2 **Results**

3 Included Trials and Patient Characteristics

Of a total of 809 searched articles, 38 were retrieved for full article review and 24 met 4 prespecified inclusion criteria and were finally included (Figure 1). A total of 14,037 patients 5 6 from 24 RCTs were included in the current meta-analysis. Among the total patients, 7,383 7 (52.6%) patients were treated with intravascular imaging-guided PCI and the remaining 6,654 8 (47.4%) patients were with angiography-guided PCI. The characteristics of the included trials 9 are summarized in Table 1. The study population of 11 trials were all-comers without restriction by angiographic lesion characteristics and the remaining 13 trials exclusively 10 11 enrolled patients with complex coronary artery lesions. Fifteen trials exclusively used IVUS, 6 trials exclusively used OCT, and the other 3 trials used both IVUS and OCT. 17 trials used 2nd 12 generation DES and the other 7 trials used bare metal stent or 1st generation DES. The follow-13 up duration of each trial ranged from 6 months to 5 years and weighted median follow-up 14 duration in the current meta-analysis was 2.0 years. 15

16 Regarding the quality of included trials, most trials were deemed to be at low risk of bias, although some criteria were unclearly described in few trials (Supplemental Figure 1 17 and Supplemental Table 4). The characteristics of patients in the included trials are presented 18 19 in **Supplemental Table 5**. Briefly, weighted mean age of the study population was 64.3 years and 75.6% were male. 64.8%, 30.5%, and 60.4% of the study population had hypertension, 20 diabetes mellitus, and dyslipidemia, respectively. 55.7% of the study population presented with 21 22 acute coronary syndrome. As only RCTs were included in the current study, baseline 23 characteristics were balanced between intravascular imaging-guided PCI and angiographyguided PCI groups. 24

1

Clinical Outcomes 2

3 Among 14,037 patients from 24 RCTs, observed rates of MACE in pooled analysis were 9.1% and 12.4% at a weighted median follow-up of 2.0 years for intravascular imaging-4 guided PCI and angiography-guided PCI groups, respectively. In random-effects model, 5 6 intravascular imaging-guided PCI was associated with a lower risk of MACE than angiography-guided PCI (RR, 0.75; 95% CI, 0.67 to 0.84; P<0.001; heterogeneity I², 18.9%) 7 8 (Figure 2). Number needed to treat to prevent one MACE was 33 (95% CI, 25 to 50). A fixedeffects model yielded similar results (RR, 0.75; 95% CI, 0.68 to 0.83; P<0.001; heterogeneity 9 I², 18.9%). The lower risk of MACE in intravascular imaging-guided PCI was driven by 10 11 significantly lower risks of MI (RR, 0.83; 95% CI, 0.70 to 0.97; P=0.019; heterogeneity I², 0.0%) and TVR (RR, 0.70; 95% CI, 0.61 to 0.79; P<0.001; heterogeneity I², 0.0%). Regarding 12 stent thrombosis, observed rates were 0.5% and 1.2% at a weighted median follow-up of 2.0 13 years for intravascular imaging-guided PCI and angiography-guided PCI groups, respectively 14 (RR, 0.50; 95% CI, 0.32 to 0.78; P=0.002; heterogeneity I², 0.0%). However, there was no 15 16 difference in the risk of all-cause death between the 2 groups (RR, 0.82; 95% CI, 0.67 to 1.01; P=0.068; heterogeneity I^2 , 0.0%) (Figure 3). 17

To assess the robustness and bias of the main results, additional analyses were 18 19 performed. Fixed-effects models yielded consistent results with those from the random-effects models for MI, TVR, and stent thrombosis. In the cumulative meta-analysis to evaluate the 20 21 temporal trend, intravascular imaging-guided PCI consistently showed a lower risk of MACE 22 than angiography-guided PCI over time from 2000 to 2023 (Supplemental Figure 2). No 23 individual study substantially influenced the pooled effect estimate for MACE (Supplemental Figure 3). Funnel plots, supported by Egger's and Begg's tests, indicated no small study bias 24

for MACE. The adjusted RRs for MACE by trim-and-fill method showed consistent results
 (RR, 0.75; 95% CI, 0.67 to 0.84; P<0.001) (Supplemental Figure 4).

3

4 Subgroup Analysis

In subgroup analysis according to the all-comers population or patients with complex 5 coronary artery lesions, intravascular imaging-guided PCI consistently showed a lower risk of 6 7 MACE than angiography-guided PCI. However, the prognostic benefit of the intravascular imaging-guided PCI was relatively higher in patients treated by 2nd generation DES than 8 previous types of stents (Interaction P value=0.014) (Figure 4). The prognostic benefit of 9 intravascular imaging-guided PCI over angiography-guided PCI was consistently observed in 10 11 both stable ischemic heart disease and acute coronary syndrome (Supplemental Figure 5). Other subgroup analyses also showed similar results (Figure 4). Although intravascular 12 imaging-guided PCI marginally reduced the risk of all-cause death in overall meta-analysis, 13 subgroup of the trials with 2nd generation DES showed significant reduction of all-cause death 14 in intravascular imaging-guided PCI group than angiography-guided PCI group (RR, 0.77; 95% 15 CI, 0.61 to 0.95; P=0.018; heterogeneity I^2 , 0.0%), which was not seen in the trials with bare 16 metal stent or 1st generation DES (Figure 5). 17

18

19 Patient and Public Involvement

No patient was involved in conceiving the research question, designing of the study,
or interpretating the results.

22

23 Discussion

24

The current updated meta-analysis compared clinical outcomes of intravascular

imaging-guided PCI versus angiography-guided PCI from 24 RCTs available to date. The 1 major findings were as follows. (1) The intravascular imaging-guided PCI significantly 2 3 reduced the risk of MACE, a composite of all-cause death, MI, or TVR, compared with angiography-guided PCI. (2) The intravascular imaging-guided PCI also significantly reduced 4 MI, TVR, and stent thrombosis, compared with angiography-guided PCI. Although overall 5 6 meta-analysis showed marginal effect of intravascular imaging-guided PCI regarding all-cause death, subgroup analysis of the trials with 2nd generation DES showed significantly reduced 7 8 risk of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI. (3) The prognostic benefit of intravascular imaging-guided PCI was consistently shown 9 across various subgroups including complex coronary artery lesions and acute coronary 10 11 syndrome.

12

13 Current Status of Intravascular Imaging-Guided PCI

Previous RCTs have reported that intravascular imaging-guided PCI reduced the risk 14 of MACE compared with angiography-guided PCI, largely by lowering the risk of repeat 15 revascularization.^{12-14 32} However, those RCTs have not been considered to be definitive due to 16 limited sample size or inclusion of highly selected coronary lesion subsets. In this regard, 17 current practice guidelines recommend the use of intravascular imaging-guided PCI as Class 18 IIa.¹² Furthermore, penetration rate of intravascular imaging in daily practice has been low, 19 although it varies across different healthcare systems or clinical indications of PCI. For 20 example, it was approximately 7.0-9.3% in the United States^{33 34} and 27.5-28.6% in South 21 Korea.35 22

23

24 Prognostic Impact of Intravascular Imaging-Guided PCI

1 Since most RCTs had only modest sample sizes to establish clinical benefit of intravascular imaging-guided PCI in terms of hard clinical events such as death, MI, or stent 2 3 thrombosis, a few observational studies assessed a larger number of patients and showed that intravascular imaging-guided PCI resulted in a lower risk of death or MI than angiography-4 guided PCI.^{33 36-38} Although previous meta-analyses presented similar results,^{39 40} inclusion of 5 both observational studies and RCTs would have caused heterogeneity and lowered the 6 7 evidence level of the results. Recently, 3 large scaled RCTs have been published and showed conflicting results regarding the prognostic benefit of intravascular imaging-guided PCI.^{29 30 41} 8 The RENOVATE-COMPLEX-PCI trial evaluated 1,639 patients with complex coronary artery 9 lesions and firstly showed a superiority of imaging-guided PCI using IVUS or OCT over 10 11 angiography-guided PCI in reducing the hard clinical end point including cardiac death and MI at a median follow-up of 2.1 years (7.7% vs. 12.3%, respectively; HR, 0.64; 95% CI, 0.45-0.89; 12 P=0.008).⁴¹ Subsequent OCTOBER trial showed that OCT-guided PCI significantly reduced 13 the risk of target vessel failure at 2 years than angiography-guided PCI in patients with complex 14 bifurcation lesions (10.1% vs. 14.1%, respectively; HR, 0.70; 95% CI, 0.50-0.98; P=0.035).²⁹ 15 16 Conversely, ILUMIEN IV trial failed to show significant prognostic benefit of OCT-guided PCI than angiography-guided PCI in patients with diabetes mellitus or complex coronary artery 17 lesions at 2 years (7.4% vs. 8.2%, respectively; HR, 0.90; 95% CI, 0.67-1.19; P=0.45).³⁰ 18

19 The current meta-analysis was performed to clarify whether intravascular imagingguided PCI would have prognostic benefit over angiography-guided PCI, especially for hard 20 clinical events such as all-cause death, MI, or stent thrombosis. Compared with previous meta-21 analyses,^{39 40} the current study included only RCTs and evaluated the largest number of 22 randomized patients. Similar to the prior results, intravascular imaging-guided PCI was 23 associated with a lower risk of MACE compared with angiography-guided PCI among all-24

1 comers and patients with complex coronary artery lesions. The results suggested that intravascular imaging-guided PCI would prevent 1 MACE event in every 33 patients 2 undergoing PCI. Importantly, it should be noted that intravascular imaging-guided PCI reduced 3 not only the risk of TVR but also the risks of hard clinical events such as MI and stent 4 thrombosis. The I² values for all clinical outcomes evaluated in the current study were less than 5 6 25%, indicating low heterogeneity among the included trials. Conversely, there was no 7 significant difference in the risk of all-cause mortality between the 2 groups in meta-analysis of overall trials. However, it should be noted that pooled analysis of the trials with 2nd 8 generation DES showed significantly reduced risk of all-cause death following intravascular 9 imaging-guided PCI than angiography-guided PCI. Considering that bare metal stent or 1st 10 11 generation DES are no longer used in contemporary PCI and that the risks of MI and stent thrombosis significantly reduced following intravascular imaging-guided PCI, it would be 12 reasonable to accept survival benefit of intravascular imaging-guided PCI in contemporary 13 practice. Currently ongoing trials will evaluate IVUS-guided PCI in all-comers with complex 14 coronary artery lesions (IMPROVE [NCT04221815] and IVUS-CHIP [NCT04854070]) or 15 unprotected left main disease (OPTIMAL [NCT04111770] and DKCRUSH-VIII 16 [NCT03770650]), or OCT-guided PCI (OCCUPI [NCT03625908]), and these trials will 17 provide additional information on the benefit of intravascular imaging-guided PCI, especially 18 19 regarding the risk of death after PCI.

20

21 Future Perspectives of Intravascular Imaging-Guided PCI

In the current study, the treatment effect of intravascular imaging-guided PCI was consistent regardless of clinical presentation, cardiovascular comorbidities, type of used stents, and presence of complex coronary lesions. However, it should be noted that the effect size of

1 the intravascular imaging-guided PCI for the risk of MACE was relatively higher in patients with complex coronary artery lesions. These results were in line with the current guidelines 2 which recommend the use of intravascular imaging-guided PCI mainly for complex coronary 3 artery lesions.^{1 2} With emerging evidences, further discussion is needed in interventional 4 societies and guidelines committees as to whether intravascular imaging-guided PCI should be 5 6 upgraded to Class I recommendation for complex coronary artery lesions. As shown in the 7 subgroup analysis, among complex coronary artery lesions, more evidence from RCTs has been 8 accumulated in chronic total occlusion, left main disease, and diffuse long lesion than other 9 complex coronary artery lesions. Integration of ongoing trials and in-depth discussion are also needed to adequately define the complex coronary artery lesion that may benefit the most from 10 11 intravascular imaging-guided PCI. In addition, it should not be underestimated that intravascular imaging-guided PCI also reduced the risk of MACE in all-comers. Concurrently, 12 efforts should be made to standardize intravascular imaging optimization criteria that are 13 practical, feasible, and prognostically well-validated. Considering low penetration rates of 14 intravascular imaging in daily practice, more efforts need to be made to increase awareness and 15 educate and support practicing interventional cardiologists.⁴² Furthermore, cost-effectiveness 16 of intravascular imaging-guided PCI should be clarified to help increase its penetration rate in 17 daily practice. 18

In the current meta-analysis, intravascular imaging-guided PCI significantly reduced the risk of MACE in both stable ischemic heart disease and acute coronary syndrome patients. However, there has been limited evidence from RCT regarding the role of intravascular imaging-guided PCI in acute coronary syndrome. Similarly, there have only been a few RCTs comparing the clinical benefit of OCT-guided PCI over angiography-guided PCI and recent two large scaled trials (ILUMIEN IV and OCTOBER) showed conflicting results.^{29 30} To date,

1 supporting evidence for OCT-guided PCI was mostly derived from RCTs which showed comparable clinical outcomes between IVUS- and OCT-guided PCI.^{20 21 43 44} Similarly, 2 subgroup analysis of the current study demonstrated no significant interaction according to the 3 type of intravascular imaging devices, suggesting similar treatment effect between IVUS- and 4 OCT-guided PCI. These results are in line with the recently published OCTIVUS trial which 5 showed comparable clinical outcomes between IVUS-and OCT-guided PCI.⁴⁴ Currently 6 7 ongoing OCCUPI (NCT03625908) trial will test the potential superiority of OCT-guided PCI 8 over angiography-guided PCI. Furthermore, since those trials are enrolling both stable ischemic 9 heart disease and acute coronary syndrome patients, their results will further enrich the evidence supporting the value of intravascular imaging-guided PCI. 10

11

12 Limitations

Some limitations should be acknowledged. First, this meta-analysis included clinically 13 and methodologically diverse studies. Although we included only RCTs to the final analysis 14 and got insignificant statistical inconsistency or heterogeneity, there were some differences in 15 16 the study design including the enrollment criteria, type of stent used, type of intravascular imaging devices and procedural optimization criteria, follow-up protocols, and adjunctive 17 pharmacotherapy after PCI. Second, the included trials were conducted from 2000 to 2023 and 18 19 significant changes in practice patterns such as stent technology, PCI technique, and 20 pharmacotherapy should be considered to interpret the results. However, the results from the 21 cumulative meta-analysis imply that treatment effect of intravascular imaging-guided PCI was 22 consistent over 20 years of period. Third, as this is a study-level meta-analysis, data of the 23 individual patients were not included in the analysis, and therefore, we could not adjust for patient-level confounders especially the differences in target lesion complexity. Fourth, this 24

meta-analysis basically composed of 24 RCTs inherently shares the limitations of each trial.
Fifth, we did not use Google Scholar or Web of Science in the initial search strategies, and
some RCTs were added manually. However, same 24 RCTs were selected even after including
these databases in search strategies and the current meta-analysis included the largest number
of RCTs than previously conducted meta-analyses. Sixth, as current study included only a small
number of patients with ST-segment elevation MI, caution is needed to extrapolate the results
to patients with ST-segment elevation MI.

8

9 **Conclusion**

10 Compared to angiography-guided PCI, intravascular imaging-guided PCI was 11 associated with a reduced the risk of MACE by lowering the risk of MI, TVR, and stent 12 thrombosis. Pooled analysis of trials with 2nd generation DES showed significantly lower risk 13 of all-cause death following intravascular imaging-guided PCI than angiography-guided PCI.

1 Acknowledgment: None.

2

3 Contributors

DH contributed to conception and design of the work, acquisition, analysis, 4 interpretation of data for the work, drafting of the manuscript. WK contributed to acquisition, 5 6 analysis, and interpretation of data for the work. SHL contributed to the conception of data for 7 the work, interpretation of data for the work, and critical revision of the manuscript. JML 8 contributed to the conception and design conception and design of the work, acquisition, analysis, interpretation of data for the work, and drafting of the manuscript. All other authors 9 contributed to interpretation of data for the work, and critical revision of the manuscript. All 10 authors approved the final version to be published. The guarantors (DH, WK, and JML) accept 11 full responsibility for the work and/or the conduct of the study, had access to the data, and 12 13 controlled the decision to publish. The corresponding authors (SHL and JML) attest that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. 14

15

16 **Funding**: None

17

18 **Competing interests**

Dr. Joo Myung Lee received an Institutional Research Grant from Abbott Vascular,
Boston Scientific, Philips Volcano, Terumo Corporation, Zoll Medical, and Donga-ST. Prof.
Joo-Yong Hahn received an Institutional Research Grant from National Evidence-based
Healthcare Collaborating Agency, Ministry of Health & Welfare, Korea, Abbott Vascular,
Biosensors, Boston Scientific, Daiichi Sankyo, Donga-ST, Hanmi Pharmaceutical, and
Medtronic Inc. Prof. Hyeon-Cheol Gwon received an Institutional Research Grant from Boston

1	Scientific, Genoss, and Medtronic Inc. All other authors declare that there are no competing
2	interests to declare.
3	
4	Ethical approval: Not required.
5	
6	Data Sharing
7	Original data used in the current meta-analysis including the analytic codes will be
8	shared upon reasonable request. Any relevant inquiry should be emailed to Dr. Joo Myung Lee
9	(Email: drone80@hanmail.net).
10	The lead author (JML) affirms that the manuscript is an honest, accurate, and
11	transparent account of the study being reported; that no important aspects of the study have
12	been omitted, and that any discrepancies from the study as planned have been explained.
13	
14	Dissemination to participants and related patient and public communities
15	There are no plans to disseminate the results to the individual study participants or the
16	relevant patient community.
17	
18	Copyright/License for Publication
19	The Corresponding Author (JML) has the right to grant on behalf of all authors and
20	does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in
21	perpetuity, in all forms, formats and media (whether known now or created in the future), to i)
22	publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution

into other languages, create adaptations, reprints, include within collections and create 1 2 summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) 3 based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be 4 located; and, vi) licence any third party to do any or all of the above. 5

All rights reserved. No reuse allowed without permission.

1 **References**

- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. *Eur Heart J* 2019;40:87-165.
 doi:10.1093/eurheartj/ehy394
- Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI Guideline for
 Coronary Artery Revascularization: A Report of the American College of
 Cardiology/American Heart Association Joint Committee on Clinical Practice
 Guidelines. *Circulation* 2022;145:e18-e114. doi:10.1161/cir.000000000001038
- 9 3 Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of
 10 thrombosis after successful implantation of drug-eluting stents. *JAMA* 2005;293:212611 30. doi:10.1001/jama.293.17.2126
- Magalhaes MA, Minha S, Chen F, et al. Clinical presentation and outcomes of coronary
 in-stent restenosis across 3-stent generations. *Circ Cardiovasc Interv* 2014;7:768-76.
 doi:10.1161/CIRCINTERVENTIONS.114.001341
- Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease:
 revascularisation and invasive strategies. *Lancet* 2015;386:702-13. doi:10.1016/S0140 6736(15)61220-X
- Raber L, Mintz GS, Koskinas KC, et al. Clinical use of intracoronary imaging. Part 1:
 guidance and optimization of coronary interventions. An expert consensus document of
 the European Association of Percutaneous Cardiovascular Interventions. *Eur Heart J*2018;39:3281-300. doi:10.1093/eurheartj/ehy285
- Fitzgerald PJ, Oshima A, Hayase M, et al. Final results of the Can Routine Ultrasound
 Influence Stent Expansion (CRUISE) study. *Circulation* 2000;102:523-30.
 doi:10.1161/01.cir.102.5.523
- Frey AW, Hodgson JM, Muller C, Bestehorn HP, Roskamm H. Ultrasound-guided
 strategy for provisional stenting with focal balloon combination catheter: results from
 the randomized Strategy for Intracoronary Ultrasound-guided PTCA and Stenting
 (SIPS) trial. *Circulation* 2000;102:2497-502. doi:10.1161/01.cir.102.20.2497
- 9 Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of coronary stent
 implantation under ultrasound or angiographic guidance to reduce stent restenosis
 (OPTICUS Study). *Circulation* 2001;104:1343-9. doi:10.1161/hc3701.096064
- Oemrawsingh PV, Mintz GS, Schalij MJ, et al. Intravascular ultrasound guidance
 improves angiographic and clinical outcome of stent implantation for long coronary
 artery stenoses: final results of a randomized comparison with angiographic guidance
 (TULIP Study). *Circulation* 2003;107:62-7. doi:10.1161/01.cir.0000043240.87526.3f
- Russo RJ, Silva PD, Teirstein PS, et al. A randomized controlled trial of angiography
 versus intravascular ultrasound-directed bare-metal coronary stent placement (the
 AVID Trial). *Circ Cardiovasc Interv* 2009;2:113-23.
 doi:10.1161/CIRCINTERVENTIONS.108.778647
- Jakabcin J, Spacek R, Bystron M, et al. Long-term health outcome and mortality
 evaluation after invasive coronary treatment using drug eluting stents with or without
 the IVUS guidance. Randomized control trial. HOME DES IVUS. *Catheter Cardiovasc Interv* 2010;75:578-83. doi:10.1002/ccd.22244
- Chieffo A, Latib A, Caussin C, et al. A prospective, randomized trial of intravascular ultrasound guided compared to angiography guided stent implantation in complex

All rights reserved. No reuse allowed without permission.

1 coronary lesions: the AVIO trial. *Am Heart J* 2013;165:65-72. 2 doi:10.1016/j.ahj.2012.09.017

- Kim JS, Kang TS, Mintz GS, et al. Randomized comparison of clinical outcomes
 between intravascular ultrasound and angiography-guided drug-eluting stent
 implantation for long coronary artery stenoses. *JACC Cardiovasc Interv* 2013;6:369 6 76. doi:10.1016/j.jcin.2012.11.009
- Kim BK, Shin DH, Hong MK, et al. Clinical Impact of Intravascular UltrasoundGuided Chronic Total Occlusion Intervention With Zotarolimus-Eluting Versus
 Biolimus-Eluting Stent Implantation: Randomized Study. *Circ Cardiovasc Interv*2015;8:e002592. doi:10.1161/CIRCINTERVENTIONS.115.002592
- 11 16 Tan Q, Wang Q, Liu D, Zhang S, Zhang Y, Li Y. Intravascular ultrasound-guided
 12 unprotected left main coronary artery stenting in the elderly. *Saudi Med J* 2015;36:54913 53. doi:10.15537/smj.2015.5.11251
- 14 17 Tian NL, Gami SK, Ye F, et al. Angiographic and clinical comparisons of intravascular
 15 ultrasound- versus angiography-guided drug-eluting stent implantation for patients with
 16 chronic total occlusion lesions: two-year results from a randomised AIR-CTO study.
 17 *EuroIntervention* 2015;10:1409-17. doi:10.4244/EIJV10I12A245
- 18 Kim JS, Shin DH, Kim BK, et al. Randomized comparison of stent strut coverage 18 following angiography- or optical coherence tomography-guided percutaneous 19 20 coronary intervention. Rev Esp Cardiol (Engl Ed) 2015;68:190-7. doi:10.1016/j.rec.2014.07.025 21
- Antonsen L, Thayssen P, Maehara A, et al. Optical Coherence Tomography Guided
 Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With
 Non-ST-Segment-Elevation Myocardial Infarction (OCTACS) Trial: Difference in
 Strut Coverage and Dynamic Malapposition Patterns at 6 Months. *Circ Cardiovasc Interv* 2015;8:e002446. doi:10.1161/CIRCINTERVENTIONS.114.002446
- Ali ZA, Maehara A, Genereux P, et al. Optical coherence tomography compared with
 intravascular ultrasound and with angiography to guide coronary stent implantation
 (ILUMIEN III: OPTIMIZE PCI): a randomised controlled trial. *Lancet* 2016;388:2618 28. doi:10.1016/S0140-6736(16)31922-5
- Ali ZA, Karimi Galougahi K, Maehara A, et al. Outcomes of optical coherence
 tomography compared with intravascular ultrasound and with angiography to guide
 coronary stent implantation: one-year results from the ILUMIEN III: OPTIMIZE PCI
 trial. *EuroIntervention* 2021;16:1085-91. doi:10.4244/EIJ-D-20-00498
- Meneveau N, Souteyrand G, Motreff P, et al. Optical Coherence Tomography to
 Optimize Results of Percutaneous Coronary Intervention in Patients with Non-ST Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized
 DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting).
 Circulation 2016;134:906-17. doi:10.1161/CIRCULATIONAHA.116.024393
- Kala P, Cervinka P, Jakl M, et al. OCT guidance during stent implantation in primary
 PCI: A randomized multicenter study with nine months of optical coherence
 tomography follow-up. *Int J Cardiol* 2018;250:98-103.
 doi:10.1016/j.ijcard.2017.10.059
- Liu XM, Yang ZM, Liu XK, et al. Intravascular ultrasound-guided drug-eluting stent
 implantation for patients with unprotected left main coronary artery lesions: A singlecenter randomized trial. *Anatol J Cardiol* 2019;21:83-90.
 doi:10.14744/AnatolJCardiol.2018.21447

All rights reserved. No reuse allowed without permission.

- Hong SJ, Mintz GS, Ahn CM, et al. Effect of Intravascular Ultrasound-Guided Drug Eluting Stent Implantation: 5-Year Follow-Up of the IVUS-XPL Randomized Trial.
 JACC Cardiovasc Interv 2020;13:62-71. doi:10.1016/j.jcin.2019.09.033
- Chamie D, Costa JR, Jr., Damiani LP, et al. Optical Coherence Tomography Versus 4 26 5 Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary 6 Interventions: The **iSIGHT** Randomized Trial. Circ Cardiovasc Interv 2021;14:e009452. doi:10.1161/CIRCINTERVENTIONS.120.009452 7
- 8 27 Gao XF, Ge Z, Kong XQ, et al. 3-Year Outcomes of the ULTIMATE Trial Comparing
 9 Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation.
 10 JACC Cardiovasc Interv 2021;14:247-57. doi:10.1016/j.jcin.2020.10.001
- Neleman T, van Zandvoort LJC, Tovar Forero MN, et al. FFR-Guided PCI Optimization
 Directed by High-Definition IVUS Versus Standard of Care: The FFR REACT Trial.
 JACC Cardiovasc Interv 2022;15:1595-607. doi:10.1016/j.jcin.2022.06.018
- Holm NR, Andreasen LN, Neghabat O, et al. OCT or Angiography Guidance for PCI
 in Complex Bifurcation Lesions. *N Engl J Med* 2023 doi:10.1056/NEJMoa2307770
- Ali ZA, Landmesser U, Maehara A, et al. Optical Coherence Tomography-Guided
 versus Angiography-Guided PCI. *N Engl J Med* 2023 doi:10.1056/NEJMoa2305861
- Stewart LA, Clarke M, Rovers M, et al. Preferred Reporting Items for Systematic
 Review and Meta-Analyses of individual participant data: the PRISMA-IPD Statement.
 Jama 2015;313:1657-65. doi:10.1001/jama.2015.3656
- 32 Hong SJ, Kim BK, Shin DH, et al. Effect of Intravascular Ultrasound-Guided vs
 Angiography-Guided Everolimus-Eluting Stent Implantation: The IVUS-XPL
 Randomized Clinical Trial. *JAMA* 2015;314:2155-63. doi:10.1001/jama.2015.15454
- Mentias A, Sarrazin MV, Saad M, et al. Long-Term Outcomes of Coronary Stenting
 With and Without Use of Intravascular Ultrasound. *JACC Cardiovasc Interv*2020;13:1880-90. doi:10.1016/j.jcin.2020.04.052
- Park DY, Vemmou E, An S, et al. Trends and impact of intravascular ultrasound and
 optical coherence tomography on percutaneous coronary intervention for myocardial
 infarction. *Int J Cardiol Heart Vasc* 2023;45:101186. doi:10.1016/j.ijcha.2023.101186
- 35 Shin DH, Kang HJ, Jang JS, et al. The Current Status of Percutaneous Coronary
 Intervention in Korea: Based on Year 2014 & 2016 Cohort of Korean Percutaneous
 Coronary Intervention (K-PCI) Registry. *Korean Circ J* 2019;49:1136-51.
 doi:10.4070/kcj.2018.0413
- Witzenbichler B, Maehara A, Weisz G, et al. Relationship between intravascular
 ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of
 dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study. *Circulation*2014;129:463-70. doi:10.1161/CIRCULATIONAHA.113.003942
- 38 37 Kinnaird T, Johnson T, Anderson R, et al. Intravascular Imaging and 12-Month
 39 Mortality After Unprotected Left Main Stem PCI: An Analysis From the British
 40 Cardiovascular Intervention Society Database. *JACC Cardiovasc Interv* 2020;13:34641 57. doi:10.1016/j.jcin.2019.10.007
- 42 38 Choi KH, Song YB, Lee JM, et al. Impact of Intravascular Ultrasound-Guided
 43 Percutaneous Coronary Intervention on Long-Term Clinical Outcomes in Patients
 44 Undergoing Complex Procedures. JACC Cardiovasc Interv 2019;12:607-20.
 45 doi:10.1016/j.jcin.2019.01.227
- 46 39 Buccheri S, Franchina G, Romano S, et al. Clinical Outcomes Following Intravascular
 47 Imaging-Guided Versus Coronary Angiography-Guided Percutaneous Coronary

All rights reserved. No reuse allowed without permission.

Intervention With Stent Implantation: A Systematic Review and Bayesian Network
 Meta-Analysis of 31 Studies and 17,882 Patients. JACC Cardiovasc Interv
 2017;10:2488-98. doi:10.1016/j.jcin.2017.08.051

- 4 40 Darmoch F, Alraies MC, Al-Khadra Y, Moussa Pacha H, Pinto DS, Osborn EA.
 5 Intravascular Ultrasound Imaging-Guided Versus Coronary Angiography-Guided
 6 Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis. *J Am*7 *Heart Assoc* 2020;9:e013678. doi:10.1161/JAHA.119.013678
- 41 Lee JM, Choi KH, Song YB, et al. Intravascular Imaging-Guided or Angiography 9 Guided Complex PCI. *N Engl J Med* 2023;388:1668-79. doi:10.1056/NEJMoa2216607
- 42 Choi KH, Lee SY, Song YB, et al. Prognostic Impact of Operator Experience and IVUS
 Guidance on Long-Term Clinical Outcomes After Complex PCI. JACC Cardiovasc
 Interv 2023;16:1746-58. doi:10.1016/j.jcin.2023.04.022
- Kubo T, Shinke T, Okamura T, et al. Optical frequency domain imaging vs.
 intravascular ultrasound in percutaneous coronary intervention (OPINION trial): oneyear angiographic and clinical results. *Eur Heart J* 2017;38:3139-47.
 doi:10.1093/eurheartj/ehx351
- Kang DY, Ahn JM, Yun SC, et al. Optical Coherence Tomography-Guided or
 Intravascular Ultrasound Guided Percutaneous Coronary Intervention: The OCTIVUS
 Randomized Clinical Trial. *Circulation* 2023
 doi:10.1161/CIRCULATIONAHA.123.066429

21

1 Figure Legends

2 Figure 1. Flow Diagram of Study Selection

The study flow diagram was depicted following the guideline of Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA).

5

6 Figure 2. Meta-Analysis Comparing Major Adverse Cardiac Event Between 7 Intravascular Imaging vs. Angiography-Guided PCI

8 Forest plots comparing major adverse cardiac event, a composite of all-cause death, myocardial 9 infarction, and target vessel revascularization between intravascular imaging-guided and 10 angiography-guided PCI. RRs with 95% CIs are displayed for individual studies and the pooled 11 overall effect.

Abbreviations: AIR-CTO, Angiographic and clinical comparisons of intravascular ultrasound-12 versus angiography-guided drug-eluting stent implantation for patients with chronic total 13 occlusion lesions; AVID, Angiography Versus Intravascular ultrasound-Directed stent 14 placement; AVIO, Angiography Vs. IVUS Optimization; CRUISE, Can Routine Ultrasound 15 16 Influence Stent Expansion; CI, indicates confidence interval; CTO-IVUS, Chronic Total Occlusion InterVention with drUg-eluting Stents guided by IVUS; **DOCTORS**, Does Optical 17 Coherence Tomography Optimize Results of Stenting; FFR-REACT, Fractional flow reserve 18 19 guided percutaneous coronary intervention optimization directed by high-definition intravascular ultrasound versus standard of care; HOME DES IVUS, Long-Term Health 20 Outcome and Mortality Evaluation After Invasive Coronary Treatment Using Drug Eluting 21 22 Stents with or without the IVUS Guidance; iSIGHT, Optical Coherence Tomography Versus 23 Intravascular Ultrasound and Angiography to Guide Percutaneous Coronary Interventions; IVUS-XPL, Impact of Intravascular Ultrasound Guidance on Outcomes of Xience Prime 24

1 Stents in Long Lesions; OCTACS, Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Nobori Stent Implantation in Patients With Non ST Segment 2 Elevation Myocardial Infarction; OCTOBER, European Trial on Optical Coherence 3 Tomography Optimized Bifurcation Event Reduction; **OPTICUS**, OPTimization with ICUS 4 5 to reduce stent restenosis; RENOVATE COMPLEX-PCI, Randomized Controlled Trial of 6 Intravascular Imaging Guidance versus Angiography-Guidance on Clinical Outcomes After 7 Complex Percutaneous Coronary Intervention; PCI, percutaneous coronary intervention; 8 **RESET**, Real Safety and Efficacy of a 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stents Implantation; ROBUST, Comparison of Biolimus A9 and 9 Everolimus Drug-Eluting Stents in Patients With ST Segment Elevation Myocardial Infarction; 10 11 **RR**, relative risk; **SIPS**, Strategy for Intracoronary Ultrasound-Guided PTCA and Stenting; TULIP, Thrombocyte activity evaluation and effects of Ultrasound guidance in Long 12 Intracoronary stent Placement; and ULTIMATE, Intravascular Ultrasound Guided Drug 13 Eluting Stents Implantation in "All-Comers" Coronary Lesions. 14

15

16 Figure 3. Meta-Analysis Comparing Clinical Outcomes Between Intravascular Imaging

17 vs. Angiography-Guided PCI

Forest plots comparing individual clinical outcomes between intravascular imaging-guided and
angiography-guided PCI. RRs with 95% CIs are displayed for individual studies and the pooled
overall effect. (A) all-cause death, (B) myocardial infarction, (C) target vessel revascularization,
and (D) stent thrombosis.

22 Abbreviations are as in Figure 2.

23

24 Figure 4. Subgroup Analysis

Forest plots of subgroup analysis comparing major adverse cardiac event, a composite of all cause death, myocardial infarction, and target vessel revascularization between intravascular
 imaging-guided and angiography-guided PCI. RRs with 95% CIs are displayed for individual

- 4 studies and the pooled overall effect.
- 5 Abbreviations are as in Figure 2.
- 6

7 Figure 5. Meta-Analysis Comparing Death Between Intravascular Imaging vs. Angio-

8 Guided Optimization Stratified by Stent Type

9 Forest plots comparing all-cause death between intravascular imaging-guided and
10 angiography-guided PCI according to type of used stents. RRs with 95% CIs are displayed for
11 individual studies and the pooled overall effect.

12 Abbreviations are as in Figure 2.

	Enroll	Median		Imaging-	Angiography-	Propor		
Trial	Period	Follow-up (year)	Study Population	guided PCI (no)	guided PCI (no)	Imaging D IVUS	evices (%) OCT	Stent Type
CRUISE	1996-1997	0.75	All patients undergoing PCI	270	229	100	0	BMS
SIPS	1996-1996	2	All patients undergoing PCI	121	148	100	0	BMS
OPTICUS	1996-1998	1	All patients undergoing PCI	273	275	100	0	BMS
TULIP	1998-2001	1	Long lesion	73	71	100	0	BMS
AVID	1995-1999	1	All patients undergoing PCI	369	375	100	0	BMS
HOME DES IVUS	2004-2005	1.5	Various complex lesions only	105	105	100	0	1 st Gen DES
AVIO	2008-2009	2	Various complex lesions only	142	142	100	0	1 st Gen DES
Kim et al. (RESET substudy)	2009-2012	1	Long lesion	269	274	100	0	2 nd Gen DES
CTO-IVUS	2012-2013	1	Chronic total occlusion	201	201	100	0	2nd Gen DES
AIR-CTO	2010-2011	2	Chronic total occlusion	115	115	100	0	2nd Gen DES
Tan et al.	2009-2012	2	Left main	61	62	100	0	2nd Gen DES
Kim et al.	2011-2012	1	All patients undergoing PCI	58	59	0	100	2nd Gen DES
OCTACS	2011-2013	0.5	Non ST-segment elevation MI	50	50	0	100	2nd Gen DES
DOCTORS	2013-2015	0.5	All patients undergoing PCI	120	120	0	100	2nd Gen DES
ROBUST	2011-2012	0.75	ST-segment elevation MI	105	96	0	100	2nd Gen DES
Liu et al.	2010-2015	1	Left main	167	169	100	0	2nd Gen DES
IVUS-XPL	2010-2014	5	Long lesion	700	700	100	0	2nd Gen DES
ILUMIEN III	2015-2016	1	All patients undergoing PCI	289	142	47	53	2nd Gen DES
ULTIMATE	2014-2017	3	All patients undergoing PCI	724	724	100	0	2nd Gen DES
iSIGHT	2015-2016	1	All patients undergoing PCI	101	49	50	50	2nd Gen DES
FFR-REACT	2017-2020	1	All patients undergoing PCI	145	146	100	0	2nd Gen DES
RENOVATE COMPLEX-PCI	2018-2021	2.1	Various complex lesions only	1092	547	74	26	2nd Gen DES
ILUMIEN IV	2018-2020	2	Various complex lesions only and diabetes mellitus	1233	1254	0	100	2 nd Gen DES
OCTOBER	2017-2022	2	True bifurcation	600	601	0	100	2nd Gen DES

Table 1. Baseline Characteristics of the Included Trials

Abbreviations: BMS, bare metal stent; DES, drug-eluting stent; Gen, generation; IVUS, intravascular ultrasound; MI, myocardial infarction; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.

Figure 1. Flow Diagram of Study Selection.




Figure 2. Meta-Analysis Comparing Major Adverse Cardiac Event Between Intravascular Imaging vs. Angio-Guided Optimization

Trial	Publication Year	RR (95% CI) Imaging Angiograph Event/Total Event/Tota	^y Weight (%) I
CRUISE	2000	0.70 (0.48, 1.01) 42/270 51/229	6.80
SIPS	2000	0.82 (0.59, 1.16) 37/121 55/148	7.59
OPTICUS	2001	1.07 (0.75, 1.52) 52/273 49/275	7.24
TULIP	2003	0.46 (0.22, 0.95) 9/73 19/71	2.23
AVID	2009	→ 0.99 (0.73, 1.33) 68/369 70/375	8.93
HOME DES IVUS	2010	0.92 (0.42, 1.98) 11/105 12/105	1.98
AVIO	2013	0.73 (0.45, 1.17) 24/142 33/142	4.66
Kim et al. (RESET substudy)	2013	0.61 (0.30, 1.23) 12/269 20/274	2.39
CTO-IVUS	2015	0.36 (0.13, 0.97) 5/201 14/201	1.21
AIR-CTO	2015	0.86 (0.54, 1.38) 25/115 29/115	4.71
Tan et al.	2015	0.48 (0.22, 1.03) 8/61 17/62	2.02
OCTACS	2015	• 0.20 (0.01, 4.06) 0/50 2/50	0.14
Kim et al.	2015	0.68 (0.12, 3.91) 2/58 3/59	0.41
DOCTORS	2016	1.50 (0.26, 8.82) 3/120 2/120	0.40
ROBUST	2018	4.57 (0.54, 38.43) 5/105 1/96	0.28
Liu et al.	2019	0.60 (0.37, 0.97) 22/167 37/169	4.49
IVUS-XPL (5Y)	2020	0.51 (0.35, 0.76) 36/700 70/700	6.30
ILUMIEN III	2021	1.21 (0.62, 2.36) 27/289 11/142	2.55
ULTIMATE (3Y)	2021	0.62 (0.44, 0.88) 47/724 76/724	7.35
ISIGHT	2021	0.97 (0.25, 3.72) 6/101 3/49	0.69
FFR-REACT	2022	0.86 (0.30, 2.51) 6/145 7/146	1.08
RENOVATE COMPLEX-PCI	2023	••• 0.63 (0.46, 0.88) 76/1092 60/547	8.17
ILUMIEN IV	2023		9.92
OCTOBER	2023	0.71 (0.52, 0.97) 59/600 83/601	8.46
Overall Random Effects Mod	del	0.75 (0.67, 0.84) 670/7383 823/6654	100.00
	Test of Overall Effec	t : RR 0.75 (95% Cl 0.67-0.84), P < 0.001, Heterogeneity I ² = 18.9%	

Test of Overall Effect : RR 0.75 (95% CI 0.67-0.84), P < 0.001, Heterogeneity I² = 18.9%

Imaging-guided PCI Better

.1

Figure 3. Meta-Analysis Comparing Clinical Outcomes Between Intravascular Imaging vs. Angiography-Guided PCI

A. Death

B. Myocardial Infarction

Trial Pub	lication Year		RR	(95% CI)	lmaging Event/Total	Angiography Event/Total	Weight (%)	Trial P	Publication Year			RR (95% CI)	Imaging / Event/Total	Angiography Event/Total	Weight (%)
CRUISE	2000		0.17 (0.01, 3.52)	0/270	2/229	0.47	CRUISE	2000		.	1.15 (0.59, 2.24)	19/270	14/229	5.71
SIPS	2000		1.22 (0.31, 4.79)	4/121	4/148	2.33	SIPS	2000 .			0.20 (0.02, 1.67)	1/121	6/148	0.58
OPTICUS	2001		5.04 (0	0.59, 42.83)	5/273	1/275	0.95	OPTICUS	2001			0.60 (0.22, 1.64)	6/273	10/275	2.55
TULIP	2003		• 1.95 (C	.18, 20.98)	2/73	1/71	0.77	TULIP	2003	• •	-	0.19 (0.02, 1.62)	1/73	5/71	0.57
AVID	2009	+	• 1.74 (0.69, 4.38)	12/369	7/375	5.11	AVID	2009	÷		1.34 (0.75, 2.39)	25/369	19/375	7.59
HOME DES IVUS	2010		1.50 (0.26, 8.79)	3/105	2/105	1.38	HOME DES IVUS	2010			0.25 (0.03, 2.20)	1/105	4/105	0.54
AVIO	2013		0.20 (0.01, 4.13)	0/142	2/142	0.47	AVIO	2013			0.83 (0.37, 1.87)	10/142	12/142	3.91
Kim et al. (RESET substudy)	2013		1.53 (0.26, 9.07)	3/269	2/274	1.37	Kim et al. (RESET substudy)	2013			0.20 (0.01, 4.22)	0/269	2/274	0.28
CTO-IVUS	2015		0.67 (0.11, 3.95)	2/201	3/201	1.37	CTO-IVUS	2015	•		0.20 (0.01, 4.14)	0/201	2/201	0.28
AIR-CTO	2015		0.86 (0.30, 2.47)	6/115	7/115	3.86	AIR-CTO	2015		-	1.33 (0.72, 2.47)	20/115	15/115	6.67
Tan et al.	2015		0.68 (0.12, 3.91)	2/61	3/62	1.41	Tan et al.	2015			0.51 (0.05, 5.46)	1/61	2/62	0.45
OCTACS	2015	•	0.33 (0.01, 7.99)	0/50	1/50	0.43	DOCTORS	2016	-		1.00 (0.06, 15.80)) 1/120	1/120	0.33
DOCTORS	2016		3.00 (0	0.12, 72.91)	1/120	0/120	0.43	ROBUST	2018			4.58 (0.22, 94.12)) 2/105	0/96	0.28
ROBUST	2018	-	• 2.75 (0	0.11,66.59)	1/105	0/96	0.43	Liu et al.	2019		-	0.84 (0.47, 1.48)	19/167	23/169	7.87
Liu et al.	2019		0.30 (0.09, 1.08)	3/167	10/169	2.68	IVUS-XPL (5Y)	2020			0.67 (0.19, 2.35)	4/700	6/700	1.60
IVUS-XPL (5Y)	2020		0.43 (0.17, 1.11)	6/700	14/700	4.79	ILUMIEN III	2021			1.15 (0.30, 4.37)	7/289	3/142	1.42
ULTIMATE (3Y)	2021		1.00 (0.61, 1.63)	31/724	31/724	18.26	ULTIMATE (3Y)	2021		•	0.47 (0.19, 1.14)	7/724	15/724	3.20
iSIGHT	2021		0.97 (0	0.09, 10.44)	2/101	1/49	0.77	ISIGHT	2021		• 34	0.40 (0.13, 1.26)	5/101	6/49	1.97
FFR-REACT	2022		3.02 (0	0.62, 14.72)	6/145	2/146	1.73	FFR-REACT	2022			0.58 (0.17, 1.92)	4/145	7/146	1.75
RENOVATE COMPLEX-PCI	2023		0.75 (0.47, 1.20)	42/1092	28/547	19.86	RENOVATE COMPLEX-PCI	2023			0.67 (0.43, 1.05)	43/1092	32/547	12.80
ILUMIEN IV	2023		0.74 (0.47, 1.16)	32/1233	44/1254	21.53	ILUMIEN IV	2023			0.81 (0.57, 1.13)	57/1233	72/1254	22.21
OCTOBER	2023		0.57 (0.29, 1.11)	13/600	23/601	9.63	OCTOBER	2023		+	0.90 (0.62, 1.32)	46/600	51/601	17.43
Overall Random Effects Mo	del	+	0.82 (0.67, 1.01)	176/7383	188/6654	100.00	Overall Random Effects Mo	odel	Ý		0.83 (0.70, 0.97)	279/7383	307/6654	100.00
	Test of Overall Eff	fect : RR 0.82 (95%	6 CI 0.67-1.01), P = 0.068, Heterog	eneity I ² = 0	0.0%			0	Test of Overa	all Effect : RR 0.83 (95	% CI 0.70-0.97), P = 0.019, He	terogeneity I ² = 0	.0%		
							1								
		.1 .2 .5 1	2 5 10							.1 .2 .5 1	2 5 10				
	Imaging-guided PCI Better Angiography-guided PCI Better								Imaging-gui	ded PCI Better	Angiography-guided PCI	Better			

C. Target Vessel Revascularization

Trial F	Publication Year			RR (95% CI)		Angiography Event/Total	Weight (%)
CRUISE	2000			0.56 (0.34, 0.92)	23/270	35/229	6.99
SIPS	2000			0.60 (0.38, 0.95)	21/121	43/148	8.00
OPTICUS	2001	÷	-	1.04 (0.65, 1.67)	31/273	30/275	7.67
TULIP	2003			0.40 (0.18, 0.91)	7/73	17/71	2.57
AVID	2009			0.68 (0.44, 1.05)	30/369	45/375	8.91
HOME DES IVUS	2010	-++		1.00 (0.33, 3.00)	6/105	6/105	1.42
AVIO	2013	-		0.64 (0.34, 1.19)	14/142	22/142	4.35
Kim et al. (RESET substudy) 2013		-	0.68 (0.33, 1.38)	12/269	18/274	3.40
CTO-IVUS	2015		-	0.50 (0.17, 1.44)	5/201	10/201	1.54
AIR-CTO	2015		-0	0.64 (0.29, 1.43)	9/115	14/115	2.71
Tan et al.	2015	-		0.42 (0.16, 1.13)	5/61	12/62	1.78
Kim et al.	2015			1.02 (0.15, 6.98)	2/58	2/59	0.46
DOCTORS	2016		•	2.00 (0.18, 21.76)	2/120	1/120	0.30
ROBUST	2018		-	2.74 (0.29, 25.92)	3/105	1/96	0.34
Liu et al.	2019			0.47 (0.20, 1.13)	7/167	15/169	2.26
IVUS-XPL (5Y)	2020			0.56 (0.37, 0.86)	31/700	55/700	9.39
ILUMIEN III	2021			1.60 (0.53, 4.81)	13/289	4/142	1.41
ULTIMATE (3Y)	2021			0.65 (0.42, 1.01)	32/724	49/724	9.14
ISIGHT	2021		•	1.47 (0.06, 35.46)	1/101	0/49	0.17
FFR-REACT	2022	•		0.17 (0.02, 1.38)	1/145	6/146	0.39
RENOVATE COMPLEX-PC	2023			0.64 (0.38, 1.07)	32/1092	25/547	6.52
ILUMIEN IV	2023	-	+	1.00 (0.72, 1.39)	66/1233	67/1254	15.70
OCTOBER	2023			0.62 (0.33, 1.14)	16/600	26/601	4.58
Overall Random Effects M	odel	•		0.70 (0.61, 0.79)	369/7383	503/6654	100.00
	Test of Overall E	ffect : RR 0.70 (95	% CI 0.61-0.79), P < 0.001	, Heterogeneity I² =	0.0%		
			1 1 1				

5 10

D. Stent Thrombosis

Trial	Publication Year		RR (95% CI)	Imaging Event/Total	Angiography Event/Total	Weight (%
AVID	2009		1.27 (0.34, 4.69)	5/369	4/375	11.39
HOME DES IVUS	2010		0.67 (0.19, 2.29)	4/105	6/105	12.73
RESET	2013 —		1.02 (0.06, 16.20)	1/269	1/274	2.54
CTO-IVUS	2015	• +	0.14 (0.01, 2.75)	0/201	3/201	2.22
AIR-CTO	2015	•	0.14 (0.02, 1.14)	1/115	7/115	4.50
OCTACS	2015		0.33 (0.01, 7.99)	0/50	1/50	1.93
Kim et al. (RESET substudy)	2015		0.34 (0.01, 8.15)	0/58	1/59	1.92
ROBUST	2018		0.91 (0.06, 14.42)	1/105	1/96	2.56
Liu et al.	2019 -		0.40 (0.08, 2.06)	2/167	5/169	7.36
IVUS-XPL (5Y)	2020		1.00 (0.14, 7.08)	2/700	2/700	5.08
ILUMIEN III	2021 —		1.48 (0.06, 36.09)	1/289	0/142	1.91
ULTIMATE (3Y)	2021	•	0.13 (0.02, 1.00)	1/724	8/724	4.51
FFR-REACT	2022		0.34 (0.01, 8.17)	0/145	1/146	1.91
RENOVATE COMPLEX-PCI	2023	• + +	0.13 (0.01, 1.12)	1/1092	4/547	4.06
ILUMIEN IV	2023		0.36 (0.14, 0.91)	6/1233	17/1254	22.62
OCTOBER	2023		1.00 (0.29, 3.44)	5/600	5/601	12.76
Overall Random Effects Mo	del	•	0.50 (0.32, 0.78)	30/6443	66/5727	100.00

Test of Overall Effect : RR 0.50 (95% CI 0.32-0.78), P = 0.002, Heterogeneity I² = 0.0%

.1 .2 .5 1 2 5 10

Imaging-guided PCI Better Angiography-guided PCI Better

.5

1 2

.1 .2

Imaging-guided PCI Better

Figure 4. Subgroup Analysis

Subgroup	No. Trials	Imaging-PCI	Angiography-PC	Į	Treatment Ef	ffect	1 2	Interaction
	NU. Mais	Event/Total	Event/Total		RR (95% CI)	P value		P value
Type of imaging devices								
Intravascular ultrasound	18	477/4721	633/4474	-	0.73 (0.64,0.83)	<0.001	18	0.375
Optical coherence tomography	9	191/2648	264/2918		0.81 (0.63,1.03)	0.088	21	0.375
Study Population								
All-comers population	11	290/2520	329/2317	-	0.85 (0.71,1.01)	0.072	0	0 509
Complex coronary artery lesions only	13	380/4863	494/4337	-	0.69 (0.59,0.79)	<0.001	19	0.508
Type of complex coronary lesions								
Chronic total occlusion	5	51/731	76/583		0.55 (0.35,0.88)	0.012	31	
Left main	4	54/477	85/401		0.57 (0.41,0.77)	<0.001	5	NA
Diffuse long lesion	6	177/2946	252/2581	-	0.61 (0.50,0.74)	<0.001	0	
Stent type								
Bare metal stent	5	208/1106	244/1098		0.85 (0.70,1.03)	0.106	38	
1st-Gen drug-eluting stents	2	35/247	45/247		0.77 (0.52,1.16)	0.213	0	0.014
2nd-Gen drug-eluting stents	17	427/6030	534/5309	•	0.70 (0.61,0.81)	<0.001	10	
Clinical presentation								
Stable ischemic heart disease	6	108/2082	172/1861		0.57 (0.45,0.72)	<0.001	0	0.024
Acute coronary syndrome	8	211/2743	235/2432		0.78 (0.63,0.95)	0.015	21	0.634
Cardiovascular risk factors								
Diabetes mellitus	5	134/1461	147/1300		0.77 (0.58,1.02)	0.070	28	NIA
Chronic kidney disease	2	37/383	46/262		0.53 (0.35,0.79)	0.002	0	NA
			1		L L			
				10 0.20 0.50 1.0 2.0	5.0 10.0	ttor		

Imaging-guided PCI Better

Figure 5. Meta-Analysis Comparing Death Between Intravascular Imaging vs. Angio-Guided Optimization Stratified by Stent Type

Trial	Publication Year	RR (95% CI) Imaging Angiograph Event/Total Event/Total	y Weight (%
Bare Metal Stents			
CRUISE	2000	0.17 (0.01, 3.52) 0/270 2/229	0.47
SIPS	2000	1.22 (0.31, 4.79) 4/121 4/148	2.33
OPTICUS	2001	5.04 (0.59, 42.83) 5/273 1/275	0.95
TULIP	2003	1.95 (0.18, 20.98) 2/73 1/71	0.77
AVID	2009	1.74 (0.69, 4.38) 12/369 7/375	5.11
Subtotal Random Effects M Heterogeneity I ² = 0.0%	/lodel (Z=1.37, P=0.171)	1.60 (0.82, 3.13) 23/1106 15/1098	9.61
First Generation Drug-Eluti	ing Stents		
HOME DES IVUS	2010	1.50 (0.26, 8.79) 3/105 2/105	1.38
AVIO	2013	• • • • 0.20 (0.01, 4.13) 0/142 2/142	0.47
Subtotal Random Effects M Heterogeneity I ² = 23.2%	/lodel (Z=0.23, P=0.814)	0.80 (0.13, 5.11) 3/247 4/247	1.86
Contemporary Generation	Drug-Eluting Stents		
Kim et al. (RESET substudy)	2013	1.53 (0.26, 9.07) 3/269 2/274	1.37
CTO-IVUS	2015	0.67 (0.11, 3.95) 2/201 3/201	1.37
AIR-CTO	2015	0.86 (0.30, 2.47) 6/115 7/115	3.86
Tan et al.	2015	0.68 (0.12, 3.91) 2/61 3/62	1.41
OCTACS	2015	0.33 (0.01, 7.99) 0/50 1/50	0.43
DOCTORS	2016	3.00 (0.12, 72.91) 1/120 0/120	0.43
ROBUST	2018	2.75 (0.11, 66.59) 1/105 0/96	0.43
Liu et al.	2019	0.30 (0.09, 1.08) 3/167 10/169	2.68
IVUS-XPL (5Y)	2020	0.43 (0.17, 1.11) 6/700 14/700	4.79
ULTIMATE (3Y)	2021	1.00 (0.61, 1.63) 31/724 31/724	18.26
ISIGHT	2021	0.97 (0.09, 10.44) 2/101 1/49	0.77
FFR-REACT	2022	3.02 (0.62, 14.72) 6/145 2/146	1.73
RENOVATE COMPLEX-PCI		0.75 (0.47, 1.20) 42/1092 28/547	19.86
ILUMIEN IV	2023	0.74 (0.47, 1.16) 32/1233 44/1254	21.53
OCTOBER	2023	0.57 (0.29, 1.11) 13/600 23/601	9.63
Subtotal Random Effects M Heterogeneity I ² = 0.0%	/lodel (Z=2.37, P=0.018)	0.77 (0.61, 0.95) 150/6030 169/5309	88.53
Overall Random Effects Mo Heterogeneity I ² = 0.0%	odel (Z=1.83, P=0.068)	0.82 (0.67, 1.01) 176/7383 188/6654	100.00

Imaging-guided PCI Better